Dostarlimab

Monoclonal antibody

Also known as TSR-042

Approvedregulatory verdict

Evidence outlook

Approved: Endometrial Cancer, Rectal Cancer [accelerated]

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Non-Small Cell Lung Cancer · Phase 3

Also approved (3)
US
  • JEMPERLI (dostarlimab-gxly): adults with stage II or III mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer (accelerated approval)Outside this platform's coverageonclive.com
  • Mismatch Repair Deficient Recurrent or Advanced Solid Tumors JEMPERLI, as a single agent, is indicated for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies ( 14.3 )] . Continued approval for this indication may be contingent upon verification
    FDA label
Product first approved 2021
EU
  • Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Endometrial Cancer
NCT07860450 · GlaxoSmithKline
2026-11-12 – 2032-11-05 · Endometrial Carcinoma, Neoplasms, Endometrial
What this study did
NCT07684599 · GlaxoSmithKline
2026-09-24 – 2031-09-18 · Neoplasms, Endometrial
What this study did
NCT05201547 · ARCAGY/ GINECO GROUP
2022-04-15 – 2029-10 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
Rectal Cancer
NCT07740720 · GlaxoSmithKline
2026-12-17 – 2030-04-01 · Neoplasms, Rectal
What this study did
Other / comorbidity
NCT05855200 · GlaxoSmithKline
2023-08-01 – 2031-03-27 · Colonic Neoplasms, Neoplasms, Colon
What this study did
NCT06256588 · GlaxoSmithKline
2024-03-21 – 2029-10-26 · Neoplasms, Head and Neck
What this study did
NCT03602859 · Tesaro, Inc.
2018-10-11 – 2029-04-30 · Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
What this study did
NCT04679064 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2020-12-01 – 2025-01-01 · Ovarian Cancer
What this study did
NCT03806049 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2019-12 – 2024-12 · Ovarian Cancer
What this study did
Phase 2/3 (2)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT03651206 · ARCAGY/ GINECO GROUP
2020-07-15 – 2029-03 · Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
What this study did
Phase 2 (55)
Endometrial Cancer
NCT07115927 · University College, London
2025-09-30 – 2031-01-31 · Endometrial Cancer
What this study did
NCT07108270 · GlaxoSmithKline
2025-11-27 – 2030-03-31 · Neoplasms, Endometrial
What this study did
NCT07013851 · Grupo Español de Investigación en Cáncer de Ovario
2025-10-01 – 2029-10-01 · MMRd/MSI-H Stage II-III Endometrial Cancer
What this study did
NCT06317311 · GlaxoSmithKline
2024-05-07 – 2028-09-30 · Carcinoma
What this study did
NCT06278857 · Queensland Centre for Gynaecological Cancer
2024-08-01 – 2028-06-30 · Endometrial Cancer Stage I, Mmr Deficiency, Endometrioid Endometrial Adenocarcinoma, Immune-related Adverse Event
What this study did
NCT04774419 · Memorial Sloan Kettering Cancer Center
2021-04-02 – 2027-02 · Endometrial Cancer
What this study did
NCT03016338 · University Health Network, Toronto
2017-11-06 – 2026-12 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05565378 · GlaxoSmithKline
2022-10-14 – 2027-12-06 · Lung Cancer, Non-Small Cell
What this study did
NCT04940637 · University of Turin, Italy
2020-12-23 – 2025-06-30 · Lung Cancer, Mesothelioma
What this study did
NCT04581824 · GlaxoSmithKline
2020-11-19 – 2024-09-10 · Lung Cancer, Non-Small Cell
What this study did
NCT06926673 · GlaxoSmithKline
2021-12-23 – 2024-05-02 · Neoplasms
What this study did
NCT03308942 · Tesaro, Inc.
2017-09-29 – 2021-08-31 · Neoplasms
What this study did
Rectal Cancer
NCT06640049 · GlaxoSmithKline
2024-10-17 – 2031-04-15 · Neoplasms, Rectal
What this study did
NCT07381777 · Gruppo Oncologico Italiano di Ricerca Clinica
2026-01-31 – 2030-12-31 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT05723562 · GlaxoSmithKline
2023-04-03 – 2029-10-11 · Neoplasms, Rectal
What this study did
NCT05239546 · University of Iowa
2023-03-24 – 2029-06-30 · Colon Cancer, dMMR Colorectal Cancer
What this study did
NCT06365970 · Ibrahim Halil Sahin
2025-01-31 – 2028-01 · MMR-D/MSI-H Colorectal Cancers
What this study did
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07408063 · University Health Network, Toronto
2026-04-27 – 2031-03-01 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT07336147 · Chang Gung Memorial Hospital
2025-12-22 – 2030-12-22 · Female
What this study did
NCT06333314 · UNICANCER
2024-07-23 – 2030-09 · Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT05700721 · M.D. Anderson Cancer Center
2023-06-02 – 2029-12-31 · Brain Metastases
What this study did
NCT06023862 · Yonsei University
2024-01-22 – 2029-12-31 · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell Carcinoma
What this study did
NCT04139902 · Diwakar Davar
2020-06-12 – 2029-12-15 · Melanoma Stage III, Melanoma Stage IV
What this study did
NCT04837209 · Massachusetts General Hospital
2021-07-21 – 2029-12-01 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT04584255 · Dana-Farber Cancer Institute
2021-01-21 – 2029-07-17 · Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
What this study did
NCT05855811 · Centre Leon Berard
2023-07-26 – 2029-03-26 · Recurrent Cancer, Primary Cancer, Second Cancer
What this study did
NCT05405192 · University of Miami
2023-03-01 – 2028-12-01 · Gestational Trophoblastic Neoplasia
What this study did
NCT06830239 · Universitaire Ziekenhuizen KU Leuven
2025-04-03 – 2028-12 · Colon Cancer Stage III
What this study did
NCT06059495 · GERCOR - Multidisciplinary Oncology Cooperative Group
2024-01-22 – 2028-09-01 · Adenocarcinoma - GEJ, Gastric Adenocarcinoma
What this study did
NCT03833479 · Grupo Español de Investigación en Cáncer de Ovario
2019-06-28 – 2028-07-31 · Cervical Cancer, Advanced Cancer
What this study did
NCT06757244 · Hopital Foch
2025-02-18 – 2028-02-18 · Pancreas Neoplasms
What this study did
NCT05526989 · H. Lee Moffitt Cancer Center and Research Institute
2022-12-28 – 2027-11 · Penile Carcinoma
What this study did
NCT03680508 · University of Hawaii
2019-12-19 – 2027-10 · Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
What this study did
NCT04068753 · University of Oklahoma
2020-02-26 – 2027-08 · Recurrent Cervix Cancer, Progressive Cervix Cancer
What this study did
NCT06238635 · Meghan Shea
2024-03-11 – 2027-07-15 · Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
What this study did
NCT04701307 · M.D. Anderson Cancer Center
2021-02-01 – 2027-04-30 · Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
What this study did
NCT05126342 · AGO Research GmbH
2023-11-01 – 2026-11-01 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT05870761 · Casey Cosgrove
2023-10-17 – 2026-07-31 · Recurrent Endometrial Serous Adenocarcinoma
What this study did
NCT04313504 · Trisha Wise-Draper
2020-11-04 – 2026-03-04 · Head and Neck Cancer
What this study did
NCT04983745 · West Cancer Center
2021-11-29 – 2025-08 · Homologous Recombination Deficient Solid Tumors
What this study did
NCT05065021 · University Health Network, Toronto
2023-02-23 – 2025-06-06 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
What this study did
NCT04493060 · Mayo Clinic
2020-12-28 – 2025-06-01 · Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03574779 · Tesaro, Inc.
2018-11-15 – 2025-03-31 · Ovarian Neoplasms
What this study did
NCT04779151 · Gustave Roussy, Cancer Campus, Grand Paris
2021-04-07 – 2025-02-25 · Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer, Biliary Tract Cancer, Platinum-sensitive Urothelial Bladder Cancer, Clear Cell Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
What this study did
NCT03654833 · University of Leicester
2019-01-28 – 2024-03-15 · Mesothelioma, Malignant
What this study did
Phase 1/2 (11)
Endometrial Cancer
NCT05559879 · University of Alabama at Birmingham
2023-08-20 – 2027-04 · Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
What this study did
NCT06385548 · Vall d'Hebron Institute of Oncology
2024-05 – 2026-04 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06879717 · iOnctura
2025-04-22 – 2028-01 · Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
What this study did
Other / comorbidity
NCT05784012 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
2023-11-13 – 2029-03 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06796907 · GlaxoSmithKline
2025-03-04 – 2028-10-10 · Tumours, Gynecological
What this study did
NCT06065462 · M.D. Anderson Cancer Center
2023-11-10 – 2027-10-01 · Ovarian Clear Cell Carcinoma
What this study did
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT06521567 · GlaxoSmithKline
2025-03-06 – 2026-10-13 · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic Tumors, Hepatoblastoma, Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Rhabdomyosarcoma
What this study did
NCT05060432 · iTeos Belgium SA
2021-09-06 – 2025-07 · Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
What this study did
NCT06655818 · GlaxoSmithKline
2021-03-09 – 2024-02-14 · Relapsed/Refractory Multiple Myeloma
What this study did
Phase 1 (17)
Endometrial Cancer
NCT03955978 · Washington University School of Medicine
2019-10-15 – 2029-02-01 · Endometrial Cancer, Cancer of the Endometrium
What this study did
NCT05819892 · M.D. Anderson Cancer Center
2023-07-17 – 2028-03-01 · Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03307785 · Tesaro, Inc.
2017-10-12 – 2024-12-11 · Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
What this study did
Rectal Cancer
NCT04926324 · University of Iowa
2022-07-07 – 2025-11-24 · Rectal Neoplasms, Rectal Neoplasm Malignant
What this study did
Other / comorbidity
NCT06551142 · GlaxoSmithKline
2024-09-30 – 2029-06-08 · Neoplasms
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT04673448 · University of Washington
2021-10-18 – 2027-09-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
What this study did
NCT05277051 · GlaxoSmithKline
2022-03-22 – 2027-08-31 · Neoplasms
What this study did
NCT02817633 · Tesaro, Inc.
2016-07-08 – 2027-03-01 · Neoplasms
What this study did
NCT04446351 · GlaxoSmithKline
2020-06-25 – 2026-12-31 · Neoplasms
What this study did
NCT05646082 · Imperial College London
2023-05-26 – 2026-12-31 · Refractory HIV Associated Kaposi Sarcoma
What this study did
NCT03843359 · GlaxoSmithKline
2019-03-12 – 2026-01-09 · Neoplasms
What this study did
NCT05980416 · Elevation Oncology
2023-08-10 – 2025-06-02 · Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
What this study did
NCT04544995 · GlaxoSmithKline
2020-10-06 – 2025-04-23 · Neoplasms
What this study did
NCT02723955 · GlaxoSmithKline
2016-06-23 – 2023-07-05 · Neoplasms
What this study did
NCT03250832 · Tesaro, Inc.
2017-08-08 – 2023-02-13 · Neoplasms
What this study did
Phase 4 (2)
Endometrial Cancer
NCT07652515 · GlaxoSmithKline
2026-08-17 – 2030-08-30 · Neoplasms, Endometrial
What this study did
NCT06897527 · GlaxoSmithKline
2025-07-15 – 2027-01-13 · Neoplasms, Endometrial
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Rectal Cancer
NCT06762405 · Centre Hospitalier Universitaire Dijon
2025-02-06 – 2030-09 · Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dostarlimab: this drugPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 1/2Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 94 furthest-along competitors are listed; 519 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(44 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dostarlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (4)
Phase 2Penile CarcinomaRecruiting
Est. primary completion 2026-11 · NCT05526989 · CT.gov ↗
What to watch
Phase 2Neoplasms, ColonRecruiting
Est. primary completion 2026-11-23 · NCT06567782 · CT.gov ↗
What to watch
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2026-11-30 · NCT04165772 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical CarcinomaActive not recruiting
Est. primary completion 2026-12-01 · NCT06238635 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2026-12-14 · NCT06317311 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2026-12-31 · NCT04446351 · CT.gov ↗
What to watch
2027 (16)
January 2027 (2)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT06879717 · CT.gov ↗
What to watch
Phase 4Endometrial CancerNot yet recruiting
Est. primary completion 2027-01-13 · NCT06897527 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2027-02 · NCT04774419 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT04837209 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1/2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT05784012 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-03-01 · NCT02817633 · CT.gov ↗
What to watch
Phase 1Endometrial CancerRecruiting
Est. primary completion 2027-03-01 · NCT05819892 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Endometrial CancerRecruiting
Est. primary completion 2027-04 · NCT05559879 · CT.gov ↗
What to watch
Phase 2Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-04-30 · NCT04701307 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2/3Ovarian Carcinosarcoma, Endometrial CarcinosarcomaRecruiting
Est. primary completion 2027-06 · NCT03651206 · CT.gov ↗
What to watch
Phase 1/2Tumours, GynecologicalRecruiting
Est. primary completion 2027-06-21 · NCT06796907 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell CarcinomaActive not recruiting
Est. primary completion 2027-08-31 · NCT06023862 · CT.gov ↗
What to watch
October 2027 (2)
Phase 1/2Ovarian Clear Cell CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT06065462 · CT.gov ↗
What to watch
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2027-10-24 · NCT06640049 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Colon Cancer Stage IIIRecruiting
Est. primary completion 2027-12 · NCT06830239 · CT.gov ↗
What to watch
2028 (10)
February 2028 (1)
Phase 2Pancreas NeoplasmsRecruiting
Est. primary completion 2028-02-18 · NCT06757244 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2FemaleRecruiting
Est. primary completion 2028-06-22 · NCT07336147 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2028-06-30 · NCT05239546 · CT.gov ↗
What to watch
Phase 3Neoplasms, Head and NeckRecruiting
Est. primary completion 2028-06-30 · NCT06256588 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT07381777 · CT.gov ↗
What to watch
Phase 2Recurrent Cancer, Primary Cancer, Second CancerRecruiting
Est. primary completion 2028-07-26 · NCT05855811 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Advanced CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT03833479 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Adenocarcinoma - GEJ, Gastric AdenocarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT06059495 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma …Recruiting
Est. primary completion 2028-10 · NCT06333314 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
2029 (4)
March 2029 (2)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2029-03-01 · NCT07013851 · CT.gov ↗
What to watch
Phase 3Colonic Neoplasms, Neoplasms, ColonRecruiting
Est. primary completion 2029-03-19 · NCT05855200 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-07-23 · NCT07684599 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Brain MetastasesRecruiting
Est. primary completion 2029-12-31 · NCT05700721 · CT.gov ↗
What to watch
2030 (7)
March 2030 (2)
Phase 3Rectal CancerNot yet recruiting
Est. primary completion 2030-03-13 · NCT07740720 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2030-03-31 · NCT07108270 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2030-04-30 · NCT07115927 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07408063 · CT.gov ↗
What to watch
August 2030 (1)
Phase 4Endometrial CancerNot yet recruiting
Est. primary completion 2030-08-30 · NCT07652515 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Endometrial CancerNot yet recruiting
Est. primary completion 2030-11-05 · NCT07860450 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026ApprovalFDA approves Jemperli under accelerated approval in dMMR locally advanced rectal cancer
US, FDA · Source ↗
24 August 2026Filing acceptedFDA accepts Jemperli sBLA in dMMR/MSI-H locally advanced rectal cancer
US, FDA · Source ↗
24 August 2026Priority reviewFDA grants priority review to Jemperli sBLA in locally advanced rectal cancer
US, FDA · Source ↗
13 July 2026Topline resultPhase 2 AZUR-1 met its primary objective in dMMR/MSI-H rectal cancer
6 August 2025Topline resultCOSTAR Lung (NCT04655976) did not meet its overall survival primary endpoint
GlaxoSmithKline · Source ↗
20 December 2024Topline resultFIRST trial meets primary PFS endpoint
GSK · Source ↗